SCHEMBL30135802

SCHEMBL30135802

COc1ccc(OCCCC(=O)N2CCC(NC(=O)OC(C)(C)C)CC2)cc1N1CCC(=O)NC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 3/20 0.41
PDE3A Q14432 3/20 0.41
CFTR P13569 2/20 0.40
CRBN Q96SW2 5/20 0.40
DDB1 Q16531 4/20 0.40
MCL1 Q07820 1/20 0.40
TNKS O95271 1/20 0.40
PARP1 P09874 1/20 0.40
PARP10 Q53GL7 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
MLKL Q8NB16 1/20 0.40
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
EPHX2 P34913 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
P2RY12 Q9H244 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25035187 1.00 PDE3B (0.41) PDE3BPDE3ACFTRCRBNDDB1
SCHEMBL25033928 0.94 PDE3B (0.41) PDE3BPDE3ACFTRCRBNDDB1
SCHEMBL25824322 0.85 CRBN (0.41) PDE3BPDE3ACFTRCRBNDDB1
SCHEMBL25035194 0.84 ALDH1A1 (0.42) PDE3BPDE3ACRBNDDB1TNKS
SCHEMBL30475454 0.84 ALDH1A1 (0.42) PDE3BPDE3ACRBNDDB1TNKS
SCHEMBL30475465 0.84 CRBN (0.41) PDE3BPDE3ACRBNTNKSPARP1
SCHEMBL25824644 0.83 DDB1 (0.42) CFTRCRBNDDB1DRD2DRD4
SCHEMBL25033926 0.78 DDB1 (0.42) CRBNDDB1TNKSPARP1PARP10
SCHEMBL25033934 0.78 CRBN (0.53) PDE3BPDE3ACRBNDDB1MCL1
SCHEMBL31255369 0.78 MEN1 (0.46) CFTRCRBNDDB1PARP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed
EP-4157849-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2023-04-05 EP disclosed
WO-2023018238-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed
WO-2023017446-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 PDE3B 4485/4885PDE3A 4515/4885CFTR 4151/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 PDE3B 3844/4885PDE3A 3815/4885CFTR 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.